<?xml version="1.0" encoding="UTF-8"?>
<p>In the current study, the physicochemical properties related to the pharmacokinetic (PK) profiles of the new compounds 
 <bold>16–20a–c</bold> were evaluated using SwissADME (
 <ext-link ext-link-type="uri" xlink:href="http://www.swissadme.ch/" xmlns:xlink="http://www.w3.org/1999/xlink">http://www.swissadme.ch/</ext-link>)
 <xref rid="CIT0053" ref-type="bibr">
  <sup>53</sup>
 </xref>. The new compounds were also evaluated for their drug-likeness score using the online Molsoft tools (
 <ext-link ext-link-type="uri" xlink:href="http://www.molsoft.com/mprop/" xmlns:xlink="http://www.w3.org/1999/xlink">http://www.molsoft.com/mprop/</ext-link>). To predict the oral activity, the new compounds were also evaluated for any violation from Lipinski’s rule
 <xref rid="CIT0054" ref-type="bibr">
  <sup>54</sup>
 </xref>. The calculated values of the new compounds were compared with those of the multi-CDKIs, flavopiridol, palbociclib, compounds 
 <bold>3</bold> and 
 <bold>10</bold>. The results of this study are presented in 
 <xref rid="t0007" ref-type="table">Table 7</xref>.
</p>
